Orally Administered Amphotericin B Nanoformulations: Physical Properties of Nanoparticle Carriers on Bioavailability and Clinical Relevance

被引:16
作者
Fairuz, Shadreen [1 ]
Nair, Rajesh Sreedharan [2 ]
Billa, Nashiru [3 ,4 ]
机构
[1] Monash Univ Malaysia, Sch Sci, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor, Malaysia
[2] Monash Univ Malaysia, Sch Pharm, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor, Malaysia
[3] Qatar Univ, Coll Pharm, QU Hlth, Doha 2713, Qatar
[4] Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, Doha 2713, Qatar
关键词
oral; amphotericin B; bioavailability; nanoparticle; clinical; SYSTEMIC FUNGAL-INFECTIONS; IN-VITRO; LIPID NANOPARTICLES; ANTIFUNGAL ACTIVITY; DELIVERY; FORMULATIONS; ANTIBIOTICS; SOLUBILITY; ABSORPTION; TOXICITY;
D O I
10.3390/pharmaceutics14091823
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Amphotericin B is an effective polyene antifungal considered as a "gold standard" in the management of fungal infections. Currently, it is administered mainly by IV due to poor aqueous solubility, which precludes its delivery orally. Paradoxically, IV administration is akin to side effects that have not been fully eliminated even with more recent IV formulations. Thus, the need for alternative formulations/route of administration for amphotericin B remains crucial. The oral route offers the possibility of delivering amphotericin B systemically and with diminished side effects; however, enterocyte permeation remains a constraint. Cellular phagocytosis of submicron particles can be used to courier encapsulated drugs. In this regard, nanoparticulate delivery systems have received much attention in the past decade. This review examines the trajectory of orally delivered amphotericin B and discusses key physical factors of nanoformulations that impact bioavailability. The review also explores obstacles that remain and gives a window into the possibility of realizing an oral nanoformulation of amphotericin B in the near future.
引用
收藏
页数:14
相关论文
共 64 条
[1]   Amphotericin B lipid preparations: what are the differences? [J].
Adler-Moore, J. P. ;
Proffitt, R. T. .
CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :25-36
[2]   Amphotericin B-conjugated biogenic silver nanoparticles as an innovative strategy for fungal infections [J].
Ahmad, Aftab ;
Wei, Yun ;
Syed, Fatima ;
Tahir, Kamran ;
Taj, Raheela ;
Khan, Arif Ullah ;
Hameed, Muhammad Usman ;
Yuan, Qipeng .
MICROBIAL PATHOGENESIS, 2016, 99 :271-281
[3]   Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization [J].
AL-Quadeib, Bushra T. ;
Radwan, Mahasen A. ;
Siller, Lidija ;
Horrocks, Benjamin ;
Wright, Matthew C. .
SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (03) :290-302
[4]   Lipid Nano Spheres (LNSs) for enhanced oral Bioavailability of amphotericin B: Development and characterization [J].
Amarji, Basant ;
Ajazuddin ;
Raghmanshi, Dharmendra ;
Vyas, S. P. ;
Kanaujia, Parijat .
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2007, 3 (03) :264-269
[5]  
[Anonymous], 2021, ENACT TRIAL MAT2203
[6]   Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies [J].
Asthana, Shalini ;
Gupta, Pramod K. ;
Jaiswal, Anil K. ;
Dube, Anuradha ;
Chourasia, Manish K. .
PHARMACEUTICAL RESEARCH, 2015, 32 (08) :2663-2677
[7]   Development of an amphotericin B micellar formulation using cholesterol-conjugated styrene-maleic acid copolymer for enhancement of blood circulation and antifungal selectivity [J].
Banshoya, Kengo ;
Kaneo, Yoshiharu ;
Tanaka, Tetsuro ;
Yamamoto, Shigechika ;
Maeda, Hiroshi .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 589
[8]  
Battaglia DP, 2013, NANOMATERIALS FOR MEDICAL APPLICATIONS, P33, DOI 10.1016/B978-0-12-385089-8.00002-9
[9]  
Berdichevski Roberto Herz, 2006, Braz J Infect Dis, V10, P94, DOI 10.1590/S1413-86702006000200005
[10]  
Bhatia Saurabh, 2014, ScientificWorldJournal, V2014, P564573, DOI 10.1155/2014/564573